High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency
Read time: 1 mins
Last updated:9th May 2012
This study will investigates the effect of high dose alkylating chemotherapy compared to standard dose chemotherapy as part of a multimodality approach in patients with oligometastatic HRD positive or BRCA1/2 related breast cancer.
|Study start date||2012-05-09|